Notícias e Atividades da Axsome Therapeutics

Axsome Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Axsome Therapeutics é uma empresa listada sob o símbolo AXSM (US).

Veja o organograma con seus 19 executivos principais

Biografias mais buscadas da Axsome Therapeutics

• Herriot Tabuteau, Chief Executive Officer and Director
• Roger Jeffs, Director
• Mark Saad, Director

Criar um alerta
para seguir os movimentos de executivos da Axsome Therapeutics.

Axsome Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Axsome Therapeutics

• Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 | Axsome Therapeutics, Inc.
• Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders | Axsome Therapeutics, Inc.
• Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event | Axsome Therapeutics, Inc.
• Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting | Axsome Therapeutics, Inc.
• Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder | Axsome Therapeutics, Inc.
• Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting | Axs
• Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry | Axsome Therapeutics, Inc.
• Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry | Axsome Therapeutics, Inc.
• Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month | Axsome Therapeutics, Inc.
• Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea | Axsome Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Axsome Therapeutics

• Axsome Therapeutics na Wikipedia, Google News e Yahoo Finance
• Axsome Therapeutics na LinkedIn, Twitter e YouTube